IRCT201008312641N3已完成4 期
Multicenter, Open-Label, Phase IV Study to Evaluate the Safety,Tolerability, and Efficacy of Tocilizumab in Patients with Active Rheumatoid arthritis on background non-biologic DMARDs who have an inadequate response to current non-biologic DMARD and/or Anti- TNF therapy
Akbarieh Company0 个研究点目标入组 100 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 65 years（—）
- 性别
- All
入选标准
- •Inclusion Criteria: age more than 18 years, moderate to severe rheumatoid arthritis (DAS28 >3.2) of 6 months duration, inadequate clinical response to non-biologic DMARDs or anti-TNF, body weight less than150 kg
排除标准
- •rheumatic autoimmune disease or inflammatory joint disease other than RA, major surgery within 8 weeks prior to screening or planned major surgery within 6 months following screening
研究者
相似试验
招募中
1 期
A Study to Evaluate Overall Health, Physical Activity and Joint Outcomes, in Participants with Severe or Moderate Hemophilia A without FVIII Inhibitors on Emicizumab ProphylaxisSevere or Moderate Hemophilia AMedDRA version: 20.0Level: LLTClassification code: 10053753Term: Hemophilia A without inhibitors Class: 10010331CTIS2023-505747-40-00F. Hoffmann-La Roche AG136
进行中（未招募）
4 期
An Open Label, Multicentre, Phase IV Study to Evaluate the Safety and Treatment Effects of Tebokan® forte (Ginkgo Biloba EGb 761®) One Tablet of 120 mg Twice Daily in Adult Patients with DementiaCTRI/2017/02/007764Dr Willmar Schwabe India Pvt Ltd150
进行中（未招募）
不适用
A study to determine the safety profile of CSL Limited's Influenza Virus Vaccine in a pediatric population aged greater than or equal to 6 months to less than 18 years.Influenza, humanEUCTR2014-004131-40-Outside-EU/EEACSL Limited2,025
进行中（未招募）
1 期
An Open-Label, Multicenter Phase IV Study assessing safety and efficacy of ribavirin (Copegus®) as part of combination therapy with peginterferon alfa-2a (Pegasys®) in selected groups of patients with chronic viral hepatitis CEUCTR2005-003932-23-SKRoche spol. s r.o.385
进行中（未招募）
不适用
An Open-Label, Multicenter Phase IV Study assessing safety and efficacy of ribavirin (Copegus®) as part of combination therapy with peginterferon alfa-2a (Pegasys®) in selected groups of patients with chronic viral hepatitis COtevrená, multicentrická studie fáze IV hodnotící bezpecnost a úcinnost ribavirinu (Copegus®) v kombinované lécbe s peginterferonem alfa-2a (Pegasys®) u vybraných skupin pacientu s chronickou virovou hepatitidou typu C.An Open-Label, Multicenter Phase IV Study assessing safety and efficacy of ribavirin (Copegus®) as part of combination therapy with peginterferon alfa-2a (Pegasys®) in selected groups of patients with chronic viral hepatitis CEUCTR2005-003932-23-CZRoche spol. s r.o.300